Sign In
Buy NERV
$4.68
-0.0700 (-1.47%)
At Close: Jun 03, 2026
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
04:05pm, Monday, 01'st Jun 2026
Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy Distinguished panel of experts in psychiatry and ne
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
01:01pm, Wednesday, 20'th May 2026
Minerva Neurosciences (NERV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Wednesday, 20'th May 2026
The heavy selling pressure might have exhausted for Minerva Neurosciences (NERV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stre
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
04:05pm, Monday, 18'th May 2026
BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nerv
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
08:00am, Tuesday, 05'th May 2026
Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–
Minerva Neurosciences, Inc (NASDAQ:NERV) Sees Significant Growth in Short Interest
05:36am, Monday, 13'th Apr 2026
Minerva Neurosciences, Inc (NASDAQ: NERV - Get Free Report) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totaling 1,020,925 shares, a grow
Minerva Announces Leadership Transition
04:05pm, Thursday, 02'nd Apr 2026
BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne
Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected 2
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
04:05pm, Wednesday, 25'th Mar 2026
Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data
Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms
01:03am, Saturday, 21'st Mar 2026
Minerva Neurosciences (NASDAQ: NERV) provided an update on its development program for roluperidone, which the company described as a potential first treatment option aimed at the negative symptoms of
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
07:00am, Thursday, 12'th Mar 2026
BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
07:00am, Wednesday, 11'th Mar 2026
Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027 Initiation of confirmatory Phase 3 tr
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
07:00am, Wednesday, 04'th Mar 2026
BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne
Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript
BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner
